Pharmacoeconomic Evaluation of Baritinib in the Treatment of Adult Patient With Moderate to Severe Rheumatoid Arthritis With Intolerance or Lack of an Adequate Response to Treatment With One or More Basic Antirheumatic Drugs in the Russian Federation
Pharmacoeconomics: theory and practice
doi 10.30809/phe.4.2019.1
Full Text
Open PDFAbstract
Available in full text
Date
December 15, 2019
Authors
Publisher
Moscow Pharmaceutical Society